The review evaluated all high-sodium oxybates, fixed-dose, and twice-nightly administrations in both oxybate-experienced patients and those who had not undergone prior treatment.
During the second quarter, Jazz Pharmaceuticals registered a 39% year-over-year growth in net product sales of its low-sodium Xywav.
Washington University School of Medicine researchers discovered an FDA-approved sleeping pill affects the levels of proteins that are critical for driving Alzheimer's disease.
The presentations include data from the SHARP study in patients with excessive daytime sleepiness associated with OSA, real-world data from OSA patients taking Sunosi as part of the SURWEY study in Germany, healthcare resource use in OSA patients with residual EDS, and effect sizes and numbers needed to treat analyses.
Read More
Tokyo-based Eisai will present eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (Dayvigo) at SLEEP 2023.
Read More
Avadel Pharmaceuticals will present new data supporting the clinical profile for Lumryz for narcolepsy in 12 abstracts at SLEEP 2023.
Read More
From sleep trackers to wakefulness drugs, the 21st century has seen an influx of new technology that could radically alter the way we sleep.
Read More
Axsome Therapeutics will present data on Sunosi, including results from the SHARP study, at the American Society of Clinical Psychopharmacology Annual Meeting, being held May 30 to June 3.
Read More
New research examines the mortality and exacerbation risks associated with non-benzodiazepine benzodiazepine receptor agonists versus other hypnotics to treat insomnia in COPD patients.
Read More
The FDA says current prescribing information for some prescription stimulants does not provide up-to-date warnings about the harms of misuse and abuse.
Read More
Jazz Pharmaceutics says the benefits of reducing sodium intake resonate with prescribers as the large majority of new-to-oxybate narcolepsy patients continue to be prescribed Xywav.
Read More
In a study comparing the effectiveness of wakefulness-promoting agents, researchers pinpointed which drug is likely the most effective in treating excessive daytime sleepiness for people with sleep apnea.
Read More
Physicians who regularly manage RLS patients offer real-world advice on ways to prevent augmentation. For patients already experiencing augmentation, new therapy options may be on the way.
Read More
Axsome Therapeutics reported first-quarter corporate updates, noting a growing patient base for Sunosi and progress for its narcolepsy drug candidate AXS-12.
Read More
According to a review of 14 trials involving patients with OSA already on conventional therapy, adverse events associated with several wakefulness drugs increased the risk of discontinuation in several trials.
Read More
The approval was supported by phase 3 results that demonstrated Quviviq improved sleep onset, sleep maintenance, and self-reported total sleep time in adults with insomnia.
Read More
The company reported business updates for the quarter ending March 31, noting continued momentum in its commercial business for Wakix, as well as in the advancement of its clinical development programs for pitolisant for the treatment of idiopathic hypersomnia.
Read More
Solriamfetol is being trialed in 59 patients with excessive daytime sleepiness associated with obstructive sleep apnea and impaired cognitive function.
Read More